FLT3 and acute myeloid leukemia: During intensive induction chemotherapy, a mid-induction bone marrow biopsy is typically performed around day 14 (D14) or day 21 (D21) (in the case of patients with FLT3-mutated AML receiving an FLT3 inhibitor) as an initial assessment of response to treatment [15,16].